BRA
VRTX icon

Bender Robert & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Bender Robert & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-27,288
Closed -$12.8M – 80
2024
Q2 		$12.8M Buy
+27,288
New +$11.8M 2.81% 11

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bender Robert & Associates's VRTX Position: Q2 2026 in Review

Bender Robert & Associates increased its Vertex Pharmaceuticals (VRTX) stake by 0.5% in Q2 2026, buying an estimated $58.5K and bringing the position to 26,303 shares worth $13.1M. The position accounts for 2.72% of the portfolio, ranked #12.

Bender Robert & Associates first reported a position in VRTX in Q1 2021 and has held it in 21 quarters since. The position peaked at $13.1M in Q1 2025. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Bender Robert & Associates held 26,303 shares of Vertex Pharmaceuticals worth $13.1M as of Q2 2026.
  • Bender Robert & Associates bought 132 Vertex Pharmaceuticals shares in Q2 2026, an estimated $58.5K.
  • Vertex Pharmaceuticals made up 2.72% of Bender Robert & Associates's portfolio in Q2 2026, its #12 holding.
  • Bender Robert & Associates first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • Bender Robert & Associates's Vertex Pharmaceuticals position peaked at $13.1M in Q1 2025.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Bender Robert & Associates's 13F filing for Q2 2026, filed 30 Jul 2026.